Trial intelligence / Profile preview

Flumatinib plus autologous transplantation versus dasatinib plus autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

ChiCTR2000034270Phase 4Recruiting

Sponsor
Affiliated Hospital of Southwest Medical University
Start
Jun 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of Flumatinib and dasatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: overall survival. Started Jun 2020; status: recruiting.

02

Drugs

Flumatinibdasatinib
03

Conditions

acute lymphoblastic leukemia (ALL)

Beyond the preview

Go deeper on ChiCTR2000034270.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2000034270.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call